Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines

被引:76
作者
Cox, SJ [1 ]
Aggarwal, N [1 ]
Statham, RJ [1 ]
Barnett, PV [1 ]
机构
[1] Inst Anim Hlth, Pirbright Lab, Pirbright GU24 0NF, Surrey, England
关键词
foot-and-mouth disease vaccine; immune responses; cytokine; antibody;
D O I
10.1016/S0264-410X(02)00691-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The ability of high potency emergency foot-and-mouth disease (FMD) vaccines to promote sustainable immune responses in sheep and pigs following a single application was examined. All vaccine formulations induced a rapid seroconversion in both species, as expected, which was maintained at near peak titres for up to 6 months in sheep and 7 months in pigs. The Montanide ISA 206 formulation gave the best results in sheep. Vaccinated pigs challenged with homologous FMDV were protected from disease at 7 months post vaccination. Systemic levels of cytokines IL-6, IL-8, and in some pigs IL-12, increased following vaccination and were often maintained at an increased level for the duration of the trials. These initial results suggest that high potency vaccines may promote longer lasting immunity than the conventional lower potency vaccines in ruminants and a comparable response in plus. Results indicate that in an outbreak situation, should emergency vaccination be done with these high potency vaccines, protection should be conferred for a long enough period for the outbreak to be brought under control without the need to revaccinate. Given the increased interval for re-vaccination the use of high potency vaccines for routine prophylactic campaigns could provide a more cost-effective and efficient means of maintaining herd immunity and is an area thus worthy of further examination. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1336 / 1347
页数:12
相关论文
共 32 条
[1]   Natural aerosol transmission of foot-and-mouth disease virus to pigs:: minimal infectious dose for strain O1 Lausanne [J].
Alexandersen, S ;
Brotherhood, I ;
Donaldson, AI .
EPIDEMIOLOGY AND INFECTION, 2002, 128 (02) :301-312
[2]   Further studies to quantify the dose of natural aerosols of foot-and-mouth disease virus for pigs [J].
Alexandersen, S ;
Donaldson, AI .
EPIDEMIOLOGY AND INFECTION, 2002, 128 (02) :313-323
[3]  
ALEXANDERSEN S, 2001, SESS STAND TECHN COM, P142
[4]  
ANDERSON EC, 1971, RES VET SCI, V12, P342
[5]  
ARNOLD R, 1995, IMMUNOLOGY, V85, P364
[6]   INTERLEUKIN-8 AND THE CHEMOKINE FAMILY [J].
BAGGIOLINI, M ;
LOETSCHER, P ;
MOSER, B .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1995, 17 (02) :103-108
[7]   Further studies on the early protective responses of pigs following immunisation with high potency foot and mouth disease vaccine [J].
Barnett, PV ;
Cox, SJ ;
Aggarwal, N ;
Gerber, H ;
McCullough, KC .
VACCINE, 2002, 20 (25-26) :3197-3208
[8]   A review of emergency foot-and-mouth disease (FMD) vaccines [J].
Barnett, PV ;
Carabin, H .
VACCINE, 2002, 20 (11-12) :1505-1514
[9]   International bank for foot-and-mouth disease vaccine: Assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants [J].
Barnett, PV ;
Pullen, L ;
Williams, L ;
Doel, TR .
VACCINE, 1996, 14 (13) :1187-1198
[10]   DEVELOPMENTS IN FOOT-AND-MOUTH-DISEASE VACCINES [J].
BARTELING, SJ ;
VREESWIJK, J .
VACCINE, 1991, 9 (02) :75-88